Please assess the completion status of the following clinical trial:

Trial Title: Imaging Studies of Kidney Cancer Using 18F-VM4-037

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Subject is greater than or equal to18 years old.~* Subject must be scheduled to undergo surgery or biopsy for primary renal cell carcinoma (RCC) greater than or equal to 2.5cm in diameter or extrarenal/extrahepatic metastatic RCC lesion (greater than or equal to1cm in diameter) at the National Institutes of Health (NIH) Clinical Center based on imaging within 3 weeks.~* Chemistry parameters: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2 times of the upper limits of normal; total bilirubin, of \< 2 times the upper limits of normal or \< 3.0 mg/dl in patients with Gilberts syndrome.~* Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.~* Ability to provide informed consent. All subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed.~* The subject has a clinically acceptable medical history, physical examination and vital signs findings during the screening period (from within 21 days before administration of 18F-VM4-037). Components of an acceptable medical history include no active infection at the time of enrollment or within 7 days of enrollment, no prior therapy that results in immunocompromise or impaired renal function (serum creatinine within 2 weeks prior to positron emission tomography (PET) imaging less than or equal to1.8 mg/dl and epidermal growth factor receptor (eGFR) must be \> 30 ml/min/1.73m\^2) or findings indicating an inability to tolerate the requirements for the scan. Previous exposure to immunocompromising therapy does not exclude the patient; patients must have an absolute neutrophil count \> 1.5/microL within 2 weeks of PET imaging.~* If female, must have a negative serum human chorionic gonadotropin (HCG) within 24 hours prior to 18F-VM4-037 injection OR be post menopausal for \> 2 years OR be surgically sterile.~EXCLUSION CRITERIA:~* Subjects for whom participating would significantly delay the scheduled standard of care therapy.~* Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.~* Subjects with severe claustrophobia unresponsive to oral anxiolytics.~* Other medical conditions deemed by the principle investigator (or associates) or sponsor to make the subject ineligible for protocol procedures.~* Female subject is pregnant or nursing~* The site of the target lesion must not have been part of a radiation portal within 6 months of enrollment.~* Subjects having received another investigational agent within 1 month before administration of 18F-VM4-037.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal Cell Carcinoma (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues